These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 23507282

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia.
    File TM, Rewerska B, Vucinic-Mihailovic V, Gonong JRV, Das AF, Keedy K, Taylor D, Sheets A, Fernandes P, Oldach D, Jamieson BD.
    Clin Infect Dis; 2016 Oct 15; 63(8):1007-1016. PubMed ID: 27448679
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Solithromycin monotherapy for treatment of community-acquired bacterial pneumonia: A meta-analysis of randomised controlled trials.
    Wen J, Chen F, Zhao M, Wang X.
    Int J Clin Pract; 2019 May 15; 73(5):e13333. PubMed ID: 30810253
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Solithromycin for the treatment of community-acquired bacterial pneumonia.
    Viasus D, Ramos O, Ramos L, Simonetti AF, Carratalà J.
    Expert Rev Respir Med; 2017 Jan 15; 11(1):5-12. PubMed ID: 27753516
    [Abstract] [Full Text] [Related]

  • 8. Solithromycin: A novel ketolide antibiotic.
    Buege MJ, Brown JE, Aitken SL.
    Am J Health Syst Pharm; 2017 Jun 15; 74(12):875-887. PubMed ID: 28432048
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia.
    File TM, Segreti J, Dunbar L, Player R, Kohler R, Williams RR, Kojak C, Rubin A.
    Antimicrob Agents Chemother; 1997 Sep 15; 41(9):1965-72. PubMed ID: 9303395
    [Abstract] [Full Text] [Related]

  • 12. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin.
    Bergallo C, Jasovich A, Teglia O, Oliva ME, Lentnek A, de Wouters L, Zlocowski JC, Dukart G, Cooper A, Mallick R, 308 Study Group.
    Diagn Microbiol Infect Dis; 2009 Jan 15; 63(1):52-61. PubMed ID: 18990531
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Population Pharmacokinetics and Safety of Solithromycin following Intravenous and Oral Administration in Infants, Children, and Adolescents.
    Gonzalez D, James LP, Al-Uzri A, Bosheva M, Adler-Shohet FC, Mendley SR, Bradley JS, Espinosa C, Tsonkova E, Moffett K, Marquez L, Simonsen KA, Stoilov S, Boakye-Agyeman F, Jasion T, Hornik CP, Hernandez R, Benjamin DK, Cohen-Wolkowiez M.
    Antimicrob Agents Chemother; 2018 Aug 15; 62(8):. PubMed ID: 29891609
    [Abstract] [Full Text] [Related]

  • 15. Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial.
    Yuan J, Mo B, Ma Z, Lv Y, Cheng SL, Yang Y, Tong Z, Wu R, Sun S, Cao Z, Wu J, Zhu D, Chang L, Zhang Y, Investigator Group of the Phase 3 Study on Oral Nemonoxacin.
    J Microbiol Immunol Infect; 2019 Feb 15; 52(1):35-44. PubMed ID: 30181096
    [Abstract] [Full Text] [Related]

  • 16. Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients.
    Shorr AF, Khashab MM, Xiang JX, Tennenberg AM, Kahn JB.
    Respir Med; 2006 Dec 15; 100(12):2129-36. PubMed ID: 16730170
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
    Anzueto A, Niederman MS, Pearle J, Restrepo MI, Heyder A, Choudhri SH, Community-Acquired Pneumonia Recovery in the Elderly Study Group.
    Clin Infect Dis; 2006 Jan 01; 42(1):73-81. PubMed ID: 16323095
    [Abstract] [Full Text] [Related]

  • 19. A multicentre, randomised, double-blind, double-dummy, parallel-controlled, phase 3 clinical trial assessing the efficacy and safety of intravenous nemonoxacin malate vs. levofloxacin for community-acquired pneumonia in adult patients.
    Li Y, Zhu D, Sun S, Chang X, Cao Z, Yang Y, Fu X, Li X, Xu J, Zhu Y, Hui F, Xu X, Chen Z, Peng L, Ma Z, Mo B, Li C, Lv Y, Zhao L, Zhu G, He Y, Liu H, Chen J, Wang Y, Liang Y, Lu Y, Qin Z, Yang H, Zhang M, Wu S, Tong Z, Ye F, Xiao Z, Wang X, Qiu C, Kuang J, Huang H, Wang K, Ying K, Jin F, Lv X, Huang Y, Liu D, Wang W, Zhang Y.
    Int J Antimicrob Agents; 2024 Aug 01; 64(2):107235. PubMed ID: 38851462
    [Abstract] [Full Text] [Related]

  • 20. High-dose levofloxacin in community-acquired pneumonia: a randomized, open-label study.
    Lee JH, Kim SW, Kim JH, Ryu YJ, Chang JH.
    Clin Drug Investig; 2012 Sep 01; 32(9):569-76. PubMed ID: 22765645
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.